Selective amyloid-β lowering agents
2008
Selective Amyloid-β Lowering Agents
publication
Author Information
Author(s): Michael S Wolfe
Primary Institution: Brigham & Women's Hospital and Harvard Medical School
Hypothesis
Blocking proteases involved in amyloid-β production may lead to effective Alzheimer's disease therapeutics.
Conclusion
The study discusses various strategies to lower amyloid-β production while preserving Notch signaling, which is crucial for cell differentiation.
Supporting Evidence
- The amyloid-β peptide is produced through the action of β- and γ-secretases.
- γ-Secretase inhibitors can cause toxicities by interfering with Notch signaling.
- Certain NSAIDs can lower amyloid-β production without affecting Notch processing.
- A cell-based screen identified compounds that lower amyloid-β while preserving Notch signaling.
Takeaway
This research is about finding ways to lower a harmful protein linked to Alzheimer's disease without causing side effects.
Methodology
The study reviews various compounds and their effects on amyloid-β production and Notch signaling.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website